Table 1 Demographic data
Patient demographics (n = 112) | ||
|---|---|---|
Age (years), mean (range) | 68 | (48–78) |
PSA (ng/mL), mean (range) | 34.5 | (1.7–276) |
median | 21 | |
Gleason | ||
7 (3 + 4), n | 17 | (15.2%) |
7 (4 + 3), n | 24 | (21.4%) |
8, n | 10 | (8.9%) |
9, n | 61 | (54.5%) |
T-stage | ||
T1, n | 24 | (21.4%) |
T2, n | 37 | (33.0%) |
T3, n | 47 | (42.0%) |
T4, n | 4 | (3.6%) |
EAU risk score | ||
Favorable* intermediate, n | 7 | (6.3%) |
Unfavorable intermediate risk, n | 6 | (5.4%) |
High risk, n | 99 | (88.4%) |
Reason for PSMA-PET/CT | ||
CT equivocal | 30 | (26.8%) |
Bone scan equivocal | 22 | (19.6%) |
Very high risk and no metastases according to BS or CT | 28 | (25.0%) |
Participation in a PSMA-study | 20 | (17.9%) |
Miscellaneous | 12 | (10.7%) |
Bone scintigraphy prior to inclusion | ||
Planar whole body | 23 | (20.5%) |
Planar whole body + SPECT/CT | 89 | (79.5%) |
Time between PSMA-PET/CT and BS (days) | ||
Median (range) | 22 | (6–80) |